Research and Development Expense (TTM) Chart

View Research and Development Expense (TTM) for LQDA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (TTM) Chart
Start Trial

Historical Research and Development Expense (TTM) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 54.95M
March 31, 2026 44.01M
December 31, 2025 38.35M
September 30, 2025 37.78M
June 30, 2025 40.29M
March 31, 2025 43.49M
December 31, 2024 46.64M
September 30, 2024 43.04M
June 30, 2024 38.60M
March 31, 2024 46.85M
December 31, 2023 42.06M
September 30, 2023 33.93M
June 30, 2023 30.90M
March 31, 2023 18.33M
December 31, 2022 17.68M
September 30, 2022 18.20M
June 30, 2022 18.15M
March 31, 2022 17.50M
Date Value
December 31, 2021 18.70M
September 30, 2021 18.33M
June 30, 2021 21.21M
March 31, 2021 24.81M
December 31, 2020 29.33M
September 30, 2020 32.17M
June 30, 2020 35.50M
March 31, 2020 37.84M
December 31, 2019 37.85M
September 30, 2019 38.43M
June 30, 2019 35.32M
March 31, 2019 31.13M
December 31, 2018 28.70M
September 30, 2018 27.49M
June 30, 2018 26.86M
March 31, 2018 26.20M
December 31, 2017 24.75M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

View Research and Development Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (TTM) Benchmarks

View Research and Development Expense (TTM) Benchmarks
Start Trial
Indivior Pharmaceuticals, Inc. 53.00M
Harmony Biosciences Holdings, Inc. 220.87M
Johnson & Johnson 15.06B
United Therapeutics Corp. 551.50M
Amneal Pharmaceuticals, Inc. 176.98M